Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-Cell lymphoma among immunocompetent individuals

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 2, 2003, Pages 208-212

  Chang, Chung Che ^a   Kampalath, Bal ^a   Schultz, Christopher ^a   Bunyi Teopengco, Ellen ^a   Logan, Brent ^a   Eshoa, Camellia ^a   Dincer, Ayse P ^a   Perkins, Sherrie L ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HISTOGENESIS; HUMAN; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; ONCOGENE C MYC; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FORMALDEHYDE; HUMANS; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE FIXATION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037329971     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Eby N, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC. Increasing incidence of primary brain lymphomas in the US. Cancer. 1988;62:2461-2465.
2. Nozaki M, Tada M, Mizugaki Y, et al. Expression of oncogenic molecules in primary central nervous system lymphomas in immunocompetent patients. Acta Neuropathol (Berl) 1998;95:505-510.
3. Xerri L, Gambarelli D, Horschowski N, Andrac L, Hassoun J. What's new in primary central nervous system lymphomas? Pathol Res Pract. 1990;186:809-816.
4. Bailey P. Intracranial sarcomatous tumours of leptomeningeal origin. Arch Surg. 1929;18:1359-1402.
5. Bonnin JM, Garcia JH. Primary malignant non-Hodgkin's lymphoma of the central nervous system. Pathol Annu. 1987;22:353-375.
6. Bergmann M, Blasius S, Bankfalvi A, Mellin W. Primary non-Hodgkin lymphomas of the CNS-proliferation, oncoproteins and Epstein-Barr-virus. Gen Diagn Pathol. 1996;141:235-242.
7. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B-cells. Blood. 1998;92:1011-1019.
8. Chang C, Liu Y, Cleveland RP, Perkins SL. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol. 2000;113:512-518.
9. King BE, Chen C, Locker J, et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. Mod Pathol. 2000;13:1219-1231.
10. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
11. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology & Genetics: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:171-174.
12. Miller TP, Grogan TM, Dahlber S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460-1466.
13. Krogh-Jensen M, Johansen P, d'Amore F. Primary central nervous system lymphomas in immunocompetent individuals: histology, Epstein-Barr virus genome, Ki-67 proliferation index, p53 and bcl-2 gene expression. Leuk Lymphoma. 1998;30:131-142.
14. Piris MA, Villuenda R, Martinez JC. p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma. 1995;17:35-42.
15. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 199E;92:234-240.
16. Zhang A, Ohshima K, Sato K, et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int. 1999;49:1043-1052.
17. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001;98:945-951.
18. Krogh-Jensen M, d'Amore F, Jensen M, et al. Clincopathologic features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant tumors in a well-defined geographical area. Leuk Lymphoma. 1995;19:223-233.
19. Deckert-Schluter M, Rang A, Wiestler OD. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system. Acta Neuropathol (Berl). 1998;96:157-162.
20. Hermann M, Scholman HJ, Marafioti T, Stein H, Schriever F. Differential expression of apoptosis, Bcl-x and c-Myc in normal and malignant lymphoid tissues. Eur J Haematol. 1997;59:20-30.
21. Hsieh T, Wu JM. Apoptosis and restriction of G(1)/S cell cycle by fenretinide in Burkitt's lymphoma mutu I cell line accessed with bcl-6 down-regulation. Biochem Biophys Res Commun. 2000;276:1295-1301.
22. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994-2004.
23. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphoma. Blood. 1992;80:758-767.